Literature DB >> 7905258

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

A J Saykin1, D L Shtasel, R E Gur, D B Kester, L H Mozley, P Stafiniak, R C Gur.   

Abstract

BACKGROUND: Medication and chronicity have complicated past attempts to characterize the neuropsychological performance of patients with schizophrenia. There have been inconsistencies regarding the pattern, selectivity, and sources of observed deficits. Our objective was to comprehensively examine neuropsychological function in patients with schizophrenia who had never been exposed to neuroleptic medication, and who were experiencing their first episode (FE) of psychosis.
METHODS: Subjects were consecutive recruitments that included 37 patients with FE schizophrenia who were never exposed to neuroleptics. These subjects were compared with 65 unmedicated, previously treated (PT) patients and 131 healthy controls.
RESULTS: The patients groups had nearly identical profiles showing generalized impairment, particularly in verbal memory and learning, attention-vigilance, and speeded visual-motor processing and attention. Verbal memory and learning accounted for most of the variance between patients and controls and removing this effect substantially attenuated all other differences. By contrast, both the FE group and PT group continued to show highly significant deficits in verbal memory and learning after controlling for attention, abstraction, and all other functions. Some functions not typically implicated in schizophrenia (spatial cognition, fine motor speed, and visual memory) were more impaired in the PT group than in the FE group.
CONCLUSIONS: Verbal memory, as a primary neuropsychological deficit present early in the course of schizophrenia, implicates the left temporal-hippocampal system. Neuropsychological evaluations before treatment permit differentiation of primary deficits from changes secondary to medication or chronicity. This is essential for developing a neurobehavioral perspective on schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905258     DOI: 10.1001/archpsyc.1994.03950020048005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  212 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

3.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

4.  A short form of the Wisconsin Card Sorting Test.

Authors:  S E Purdon; B Waldie
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

5.  Hippocampal pyramidal cell disarray correlates negatively to cell number: implications for the pathogenesis of schizophrenia.

Authors:  S A Jönsson; A Luts; N Guldberg-Kjaer; A Brun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

6.  Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status.

Authors:  Kate B Carey; Michael P Carey; Jeffrey S Simons
Journal:  J Nerv Ment Dis       Date:  2003-05       Impact factor: 2.254

Review 7.  Profiles of neuropsychologic function in schizophrenia.

Authors:  J Daniel Ragland
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 8.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 9.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 10.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.